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PRL gene-encoded prolactin is synthesized in the ribosome in the pituitary 
and then secretes into blood circulation to reach its target organ and exerts its 
biological roles, for example, involving in production, growth, development, 
immunoregulation, and metabolism. Multiple post-translational modifications 
and other unknown factors might be involved in this process to cause different 
prolactin proteoforms with differential isoelectric point (pI) and relative mass 
(Mr). Pituitary adenomas are the common disease occurring in pituitary organ 
to affect the endocrine system. Two-dimensional gel electrophoresis (2DGE) 
was used to separate prolactin proteoforms according to their pI and Mr, fol-
lowed by identification with Western blot and mass spectrometry (MS) analyses. 
Six prolactin proteoforms were identified in control pituitary tissues, and this 
prolactin proteoform pattern was significantly changed in different hormone 
subtypes of nonfunctional pituitary adenomas (NF−, LH+, FSH+, and LH+/
FSH+) and prolactinomas (PRL+). Further, bioinformatics analysis revealed 
that different prolactin proteoforms might bind to different short- or long-PRL 
receptor-mediated signaling pathways. These findings clearly demonstrated that 
prolactin proteoform pattern existed in human pituitary and changed in differ-
ent subtypes of pituitary adenomas. It is the scientific data to in-depth study 
prolactin functions, and to discover the prolactin proteoform biomarkers for 
PRL-related adenomas.
Keywords: prolactin proteoforms, pituitary, pituitary adenomas, nonfunctional 
pituitary adenomas, prolactinomas, biomarker
1. Introduction
Prolactin (PRL) is a multifunctional hormone which is synthesized and 
secreted by pituitary [1]. Human PRL gene is located on chromosome 6 [2]. The 
secretory mode of PRL is autocrine and paracrine [3], and the secretion of PRL is 
pulsating and circadian rhythm [4]. The concentration of PRL in human serum 
has a certain reference range, and when its concentration is too high or too low, 
it will have a certain impact on the body. Dopamine can inhibit the secretion of 
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PRL, and there are cases where dopamine is used to treat hyperprolactinemia [1]. 
PRL’s biological functions include production, growth, development, immu-
noregulation, and metabolism [5, 6]. PRL can exert its biological functions 
only when it binds to its receptor and activates some signaling pathways [7]. 
According to the concept of proteoforms, a protein is defined as a set of proteo-
forms, due to different splicing, post-translational modifications (PTMs), and 
even unknown factors. Each proteoform has its own specific isoelectric point 
(pI) and molecular weight (Mr). For human PRL in the UniProt protein database, 
its pI is 6.5 and Mr is 25.88 kDa. However, Ben-Jonathan et al. found that human 
serum contained PRLs with Mr > 100, 40–60 and 16 kDa, besides the PRL with 
25.88 kDa [8]. Qian et al. found six PRLs with different pI and Mr in human 
pituitary tissues by two-dimensional gel electrophoresis (2DGE) and mass 
spectrometry (MS) [9]. Similarly, Zhan et al. found 24 growth hormone (GH) 
with different pI and Mr in human pituitary tissues by 2-DGE and MS [10]. A 
possible reason of this difference of pI and Mr in human PRL and GH is that they 
undergo PTMs or splicing [11]. A proteoform is a specific form that protein exerts 
its final functions, which is derived from a gene undergoing splicing, transcrip-
tion, translation, PTMs, translocation/re-distribution, and interaction with other 
molecules, etc. [12].
Recently 2DGE and MS have been recognized as high throughput and useful 
tool to study proteoforms [13–15]. 2DGE is able to separate each proteoform 
in the first dimension—isoelectric focusing (IEF) based on proteoform charge 
difference, and in the second dimension—sodium dodecyl sulfate polyacryl-
amide gel electrophoresis (SDS-PAGE) based on proteoform relative mass 
difference [16]. Therefore, 2DGE achieves proteoform separation based on the 
difference in pI and Mr of proteoforms. And then the protein (exactly proteo-
forms) on the 2D gel is transferred to a polyvinylidene fluoride membrane for 
detection with a specific antibody. The immunoreactive positive 2D gel spots 
represent the proteoforms of a protein. The proteoform in each immunoreac-
tive positive spot was subjected to in-gel digestion with trypsin, and identifica-
tion with MS [17, 18]. MS is a key technique to identify organic molecules and 
analyze the extreme structure of certain substances [19]. Especially, top-down 
MS can quickly and extremely accurately determine the molecular weight of 
biomacromolecules, which enables proteomics research from protein general 
identification to advanced structural studies and protein-protein interaction 
studies. Moreover, with the development of MS technology, the accuracy and 
sensitivity of mass spectrometers have been greatly improved. MS has its 
absolute advantages in the use of less sample, faster analysis, and simultane-
ous separation and identification. Therefore, 2DGE in combination with MS is 
presenting as a super-high approach in separation and identification of large-
scale human proteoforms [14]. If the stable isotope labeling is introduced to 
prepare the protein sample prior to 2DGE-MS, then 2DGE-MS can also quantify 
the abundance of a proteoform between two given conditions such as tumors 
vs. controls [20].
Pituitary adenomas are the common disease occurred in pituitary organ to 
severely impact on the human endocrine system. PRL is an important pituitary 
hormone. It has important scientific merit in clarification of PRL proteoform 
pattern changed in different subtypes of pituitary adenomas compared to control 
pituitaries. This book chapter focuses on the PRL proteoforms in human pituitary 
and investigates the PRL proteoform pattern alterations in pituitary adenomas 
relative to controls, with 2DGE and MS. These findings provide the scientific data 
to in-depth study the PRL functions and to discover PRL proteoform biomarker for 
PRL-related adenomas.
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2. Methods
2.1 Pituitary tissue samples and preparation of protein samples
Eight human post-mortem control pituitary tissues, five PRL-positive prolactinoma 
tissues, three non-hormone expressed nonfunctional pituitary adenoma (NF-NFPA) 
tissues, three luteinizing hormone (LH)-positive NFPA tissues, three follicle-stimu-
lating hormone (FSH)-positive NFPA tissues, and three LH/FSH-both positive NFPA 
tissues were used to extract proteins, with the previously described procedure [21, 22]. 
The extracted protein of each tissue sample was used for 2DGE and MS analysis.
2.2 2DGE
A amount (70 μg) of proteins was diluted into 350 μL of protein sample buffer 
(7 mol/L urea, 2 mol/L thiourea, 40 g/L CHAPS, 100 mmol/L dithiothreitol (DTT), 
5 mol/L immobilized pH gradient (IPG) buffer pH 3–10 NL, and a trace of bromo-
phenol blue, followed by rehydration (18 h, 20°C) of precast IPG strips pH 3–10 NL 
(180 x 3 × 0.5 mm) in 18-cm IPG strip holder on an IPGphor instrument, and IEF 
(25°C) with parameters (Gradient 250 V and 1 h for 125 Vh, gradient at 1000 V and 
1 h for 500 Vh, gradient at 8000 V and 1 h for 4000 Vh, step-and-hold at 8000 and 
4 h for 32,000 Vh, step-and-hold at 500 V and 0.5 h for 250 Vh to achieve a total of 
36,875 Vh). After IEF, the proteins on IPG strip were reduced (15 min) with DTT, 
and alkylated with iodoacetamide, followed by separation with 12% SDS-PAGE 
(250 × 215 × 1.0 mm) in an Ettan DALT II system (GE Healthcare, up to 12 gels at 
a time) with a constant voltage (250 V, 360 min). All 2DGE-arrayed proteins were 
stained with silver-staining [23], and then digitized and analyzed with Discovery 
Series PDQuest 2D Gel Analysis software [24, 25]. Each sample was performed for 
3–5 times.
2.3 2DGE-based Western blot
The proteins in the 2D gel were partially transferred to a polyvinylidene fluoride 
(PVDF) membrane (0.8 mA/cm2 for 80 min) using Amersham Pharmacia Biotech 
Nova Blot semi-dry transfer instrument, followed by blocking (1 h, room tem-
perature) with bovine serum albumin (BSA), incubation (1 h, room temperature) 
with rabbit anti-hPRL antibodies, incubation (1 h, room temperature) with goat 
anti-rabbit alkaline phosphatase conjugated IgG, and visualization with 5-bromo-4-
chloro-3-indolyl phosphate. The detailed procedure was described previously [9].
2.4 In-gel digestion with trypsin and MS identification of PRL
The proteins in each Western blot-positive spot was performed in-gel digestion 
with trypsin, purification of tryptic peptides with ZipTipC18, followed by analysis 
with three types of MS instruments, including MALDI-TOF MS [24], LC-ESI-Q-IT 
MS [24], and MALDI-TOF-TOF MS [9]. The detailed procedure was described 
previously [9, 24]. The obtained peptide mass fingerprint (PMF) and tandem mass 
spectrometry (MS/MS) data were used to search Swiss-Prot human database for 
protein determination and PTM analysis.
2.5 Bioinformatics and statistical analysis
The phosphorylation sites, O-glycosylation sites, and N-glycosylation 
sites in the PRL amino acid sequence were predicted with NetPhos 3.1 Server 
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(http://www.cbs.dtu.dk/services/NetPhos) [26, 27], NetOGlyc 4.0 Server (http://
www.cbs.dtu.dk/services/NetOGlyc) [28], and NetNGlyc 1.0 Server (http://www.cbs.
dtu.dk/services/NetNGlyc) [29]. The PRL proteoform pattern changes were tested 
with the Chi-square test among different subtypes of pituitary adenomas (p < 0.05).
3. Results and discussion
3.1 The amino acid sequences of human PRL prohormone and mature PRL
In human pituitary, the PRL prohormone is synthesized in the ribosome, with 
227 amino acids (position 1–227; 25.9 kDa), containing a signal peptide (posi-
tion 1–28) (Table 1), which was assigned with Swiss-Prot accession No. P01236. 
However, the mature human PRL only contains 199 amino acids (position 29–227; 
22.9 kDa), which removed the signal peptide (position 1–28), and secreted into the 
circulation system to bind to its target organ for exerting PRL function.
3.2 PRL proteoform pattern in human pituitaries
The PRL proteoform pattern was found in human pituitaries. Qian et al. [9] found 
six PRL proteoforms with 2DGE in human pituitaries and then verified four of six PRL 
proteoforms with 2DGE-based Western blot in human pituitaries (Figures 1 and 2). 
The pI and Mr of these PRL proteoforms are slightly different. Each PRL proteoform 
was digested with trypsin, and followed by MS and MS/MS analysis (Figures 3 and 4). 
 The characteristic tryptic peptide are calculated to determine whether the signal 
peptide (position 1–28) in each PRL proteoform (Table 2), which was compared to the 
observed ions of each PRL proteoform. It found all PRL proteoforms all contained the 
tryptic peptide sequence MNIKGSPWK (position 1–9), which clearly demonstrated 
that six PRL proteoforms are all PRL prohormone, but not mature PRL.
3.3  PRL proteoform changes in human pituitary adenomas compared to 
controls
The PRL proteoform pattern changed in different subtypes of pituitary adeno-
mas compared to control pituitaries (Table 3). The ratio of each subtype of pituitary 
10 20 30 40 50
MNIKGSPWKG SLLLLLVSNL LLCQSVAPLP ICPGGAARCQ VTLRDLFDRA
60 70 80 90 100
VVLSHYIHNL SSEMFSEFDK RYTHGRGFIT KAINSCHTSS LATPEDKEQA
110 120 130 140 150
QQMNQKDFLS LIVSILRSWN EPLYHLVTEV RGMQEAPEAI LSKAVEIEEQ
160 170 180 190 200
TKRLLEGMEL IVSQVHPETK ENEIYPVWSG LPSLQMADEE SRLSAYYNLL
210 220
HCLRRDSHKI DNYLKLLKCR IIHNNNC
Reproduced from Qian et al. [9], with copyright permission from Frontiers in open access article, copyright 2018.
Table 1. 
Human PRL prohormone amino acid sequence (position 1–227) and mature PRL (position 29–227). The signal 
peptide is position 1-28 in the bold letters.
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adenoma relative to control pituitaries was decreased or unchanged. The propor-
tional ratio of six PRL proteoforms among five subtypes of pituitary adenomas was 
changed (Table 4 and Figure 5). In FSH+/LH+ and PRL+ pituitary adenomas, the 
proportion of PRL proteoform v1 is the largest. In FSH+ pituitary adenoma, the pro-
portion of PRL proteoform v5 is the largest. The PRL proteoform changes suggest 
their scientific merit for clinical application.
3.4  Bioinformatics prediction of potential factors to form PRL proteoforms and 
pathway networks
PRL is a hormone which is secreted by pituitary gland. PRL has a variety of 
biological functions. Only when it reaches a specific target organ and binds to its 
receptor can it play its biological function (Figure 6). PRL can bind to short PRL 
receptor or long PRL receptor and then plays its biological functions. The long or 
short PRL receptors definitely bind to different PRL proteoforms. PRL proteoforms 
are definitely derived from a PRL gene undergoing splicing, transcription, transla-
tion, PTMs, translocation/re-distribution, and interaction with other molecules, 
etc. Therefore, phosphorylation sites in hPRL (position 1–227) were predicted 
Figure 1. 
PRL proteoform pattern in human pituitaries with a 2DGE gel image. Reproduced from Qian et al. [9], with 
copyright permission from Frontiers in open access article, copyright 2018.
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with NetPhos 3.1 Server with a score more than 0.5. It obtained 22 statistically 
significantly phosphorylation sites in hPRL (position 1–227). N-glycosylation sites 
in hPRL (position 1–227) were predicted with NetNGlyc 1.0 Server with score 
more than 0.5. It obtained 10 statistically significant N-glycosylation sites in hPRL 
(position 1–227). O-glycosylation sites in hPRL (position 1–227) were predicted 
with NetOGlyc 4.0 Server with score more than 0.5. It obtained six statistically 
significant O-glycosylation sites in hPRL (position 1–227). These data suggest that 
PTMs such as phosphorylation and glycosylation might be the important reason to 
cause the PRL proteoforms.
Figure 2. 
Verification of PRL proteoforms with 2DGE-based Western blot in human pituitaries. (A) Western blot image. 
(B) Silver-stained image. Reproduced from Qian et al. [9], with copyright permission from Frontiers in open 
access article, copyright 2018.
Figure 3. 
PMF analysis of hPRL that was contained in spot v6. Reproduced from Qian et al. [9], with copyright 
permission from Frontiers in open access article, copyright 2018.
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3.5 Potential clinical application of PRL proteoform pattern
Prolactin synthesized in the ribosome in the pituitary secretes into blood 
circulation to reach its target organ and exert its biological roles, which is closely 
associated with multiple physiological and pathological processes, including 
pituitary adenomas. This study found six PRL proteoforms with different with 
differential isoelectric point (pI) and relative mass (Mr) in control pituitary tissues, 
which were identified with 2DGE coupled with Western blot and MS. This prolactin 
Figure 4. 
MS/MS analysis of the tryptic peptide 118SWNEPLYHLVTEVR131 that was derived from PRL in spot v6. 




Position Characteristic tryptic peptide sequence Observed 
[M + H]+
505.2803 1–4 MNIK −
1060.5608 1–9 MNIKGSPWK +
3930.1893 1–38 MNIKGSPWKGSLLLLLVSNLLLCQSVAPLPICPGGAAR −
574.2983 5–9 GSPWK −
3443.9268 5–38 GSPWKGSLLLLLVSNLLLCQ SVAPLPICPGGAAR −
2888.6463 10–38 GSLLLLLVSNLLLCQSVAPL PICPGGAAR −
3589.0154 10–44 GSLLLLLVSNLLLCQSVAPL PICPGGAARCQVTLR −
954.5189 29–38 LPICPGGAAR −
1654.8879 29–44 LPICPGGAARCQVTLR −
2301.1954 29–49 LPICPGGAARCQVTLRDLFD R −
+, this peptide ion was observed with mass spectrometry in each MS spectrum.  
−, this peptide was not observed with mass spectrometry.  
Reproduced from Qian et al. [9], with copyright permission from Frontiers in open access article, copyright 2018.
Table 2. 
Characteristic tryptic peptides to determine signal peptide (position1–28) within human PRL proteoforms in 
human pituitary.
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PRL proteoform NF− (%) FSH+/LH+ (%) FSH+ (%) LH+ (%) PRL+ (%)
V1 2.64 53.34 24.24 9.45 40.48
V2 1.56 2.03 0.52 3.08 11.90
V3 0.31 6.57 7.66 19.65 11.91
V4t 31.83 10.14 9.18 15.08 11.90
V5 31.83 10.52 52.47 27.53 11.91
V6 31.83 17.40 5.93 25.21 11.90
Total 100.00 100.00 100.00 100.00 100.00
Reproduced from Qian et al. [9], with copyright permission from Frontiers in open access article, copyright 2018.
*Chi-square test = 360.606, p = 0.000 (p < 0.01) among five subtypes of pituitary adenomas.
Table 4. 





















V1 P01236 6.1 26.0 −8.3 −99.9 −46.2 −12.6 −3.4
V2a P01236 6.3 26.4 −4.9 −3.8 1 −4.1 1
V3 P01236 6.3 27.9 1 −12.3 −14.6 −26.2 1
V4b P01236 6.5 26.1 −100 −19.0 −17.6 −20.1 1
V5 P01236 6.8 25.9 −100 −19.7 −100 −36.7 1
V6 P01236 6.7 25.9 −100 −32.6 −11.3 −33.6 1
Modified from Qian et al. [9], with copyright permission from Frontiers in open access article, copyright 2018.
aCharacterized with LC-ESI MS/MS.
bCharacterized with LC-ESI-MS/MS and MALDI-TOF PMF.
All other proteins were characterized with MALDI-TOF PMF. Con, control; −, decreased relative to controls; −100, 
lost relative to controls; 1, no change relative to controls; Mr, kDa.
Table 3. 
Prolactin proteoform pattern changed in different subtypes of pituitary adenomas compared to control 
pituitaries.
Figure 5. 
Proportional ratio changes of PRL proteoforms among five subtypes of pituitary adenomas. Reproduced from 
Qian et al. [9], with copyright permission from Frontiers in open access article, copyright 2018.
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proteoform pattern was significantly changed among different hormone-subtypes 
of nonfunctional pituitary adenoma (NF−, LH+, FSH+, and LH+/FSH+) and prolacti-
noma (PRL+) tissues. This result suggests the potentially important clinical value of 
serum PRL proteoforms. The reason is that pituitary tissues are impossible to obtain 
for clinical diagnosis, and prolactin must secrete into blood to exert its biological 
roles, we strongly believe serum PRL proteoforms exist and the serum PRL pro-
teoform pattern changes among different pituitary adenomas. Therefore, we will 
further analyze serum PRL proteoform pattern changes among different subtypes 
of pituitary adenomas, and develop the PRL proteoform pattern as biomarker for 
prediction, diagnosis, or prognostic assessment of pituitary adenoma occurrence, 
progression, and prognosis.
4. Conclusions
Six PRL proteoforms were identified in human pituitary tissue with 2DGE and 
MS analyses, and four of six PRL proteoforms were validated with 2DGE-based 
Western blot, MS, and MS/MS analyses. There were significant differences in PRL 
proteoform pattern among five different subtypes of pituitary adenomas (LH+, 
NF−, FSH+, FSH+/LH+, and PRL+) (P < 0.05). Moreover, MS analysis revealed that 
six PRL proteoforms are PRL prohormone. PRL proteoforms might be derived from 
PTMs such as phosphorylation, deamidation, and glycosylation. Further, different 
PRL proteoforms might bind to different PRL receptors to produce different physi-
ological functions. These findings provide scientific basis for in-depth understand-
ing of pituitary adenomas, and help develop biomarkers for treatment of pituitary 
adenoma patients. The serum PRL proteoform pattern has important clinical 
application value for prediction, diagnosis, and prognostic assessment of pituitary 
adenomas.
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